Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Correspondence

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e183-e185. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0152

View: 356 Download: 10 Crossref: 1

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0125

View: 405 Download: 20

Original Article

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 2431 Download: 416 Crossref: 12

Letter to the Editor

Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults

Donghee Kim, Won Kim, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(1):e5-e7. Published online October 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0849

View: 873 Download: 39 Crossref: 1

Review

Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

Pojsakorn Danpanichkul, Kanokphong Suparan, Vitchapong Prasitsumrit, Aijaz Ahmed, Karn Wijarnpreecha, Donghee Kim

Clin Mol Hepatol. 2025;31(1):74-89. Published online October 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0631

View: 3384 Download: 359 Web of Science: 7 Crossref: 10

Letter to the Editor

Leukocyte telomere shortening in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific mortality

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):982-986. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0691

View: 1634 Download: 64 Web of Science: 1 Crossref: 1

Original Article

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023

Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2024;30(4):756-770. Published online June 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0318

View: 2411 Download: 106 Web of Science: 6 Crossref: 7

Review

Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(Suppl):S43-S57. Published online November 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0351

View: 6298 Download: 201 Web of Science: 49 Crossref: 52

Editorial

The current trends in the health burden of primary liver cancer across the globe

Peter Konyn, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2023;29(2):358-362. Published online March 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0092

View: 4290 Download: 77 Web of Science: 9 Crossref: 9

Review

Evaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease

Karn Wijarnpreecha, Elizabeth S. Aby, Aijaz Ahmed, Donghee Kim

Clin Mol Hepatol. 2021;27(2):221-235. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0239

View: 10228 Download: 375 Web of Science: 32 Crossref: 38

Letter to the Editor

Current Burden of MASLD, MetALD, and Hepatic Fibrosis among US Adults with Prediabetes and Diabetes, 2017-2023

Donghee Kim, Rohit Loomba, Aijaz Ahmed

Received December 20, 2024 Accepted December 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1150 [Accepted]

View: 1091 Download: 139

1 |

Viewed By 8497	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7424	MAFLD: How is it different from NAFLD?
Viewed By 5390	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5013	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4551	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 319	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 291	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 186	MAFLD: How is it different from NAFLD?
Cited By 101	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 92	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search